Puma Biotechnology raises 2026 guidance. Q3 results test Puma Biotechnology stock

Published on 10/21/2026 at 01:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nerlynx revenue hit USD 95.5 million in the first half of 2026, up 3.5 percent year over year. November 5 results test Puma Biotechnology stock.

Guidance points to higher revenue

Puma raised 2026 net product revenue guidance to USD 205 million to USD 209 million on October 12, 2026.
GAAP net income reached USD 8.19 million in the second quarter of 2026.
Q3 earnings are scheduled for November 5, 2026, after the market closes.
Market capitalization stood at USD 555.4 million on October 20, 2026.

PBYI, US74587V1070, Illustration mit AI erstellt.

Puma Biotechnology (ISIN US74587V1070) raised its 2026 net product revenue guidance to USD 205 million to USD 209 million, according to Benzinga on October 12, 2026. MarketBeat lists the next quarterly results for November 5, 2026, after the market closes, giving Puma Biotechnology stock a defined near-term event.

Q2 revenue set the new base

Puma reported USD 56.50 million of total revenue for the second quarter of 2026, while GAAP net income reached USD 8.19 million. The prior quarter produced revenue of USD 44.81 million and a GAAP net loss of USD 3.75 million, according to the company figures carried by the finance record and the earnings-call transcript.

Net product revenue from NERLYNX was USD 53.60 million in the second quarter, up from USD 49.20 million in the second quarter of 2025. The increase gives the guidance revision a concrete operating base rather than relying only on pipeline expectations.

What changed in 2026 guidance?

Management lifted the earlier net product revenue range of USD 202 million to USD 206 million to USD 205 million to USD 209 million for fiscal year 2026. The same call placed full-year net income guidance at USD 17 million to USD 20 million, compared with the earlier range of USD 16 million to USD 19 million. Zacks reported that first-half 2026 NERLYNX net product revenue reached USD 95.5 million, up 3.5 percent year over year.

Three dates define the pipeline

On September 17, 2026, Puma initiated ALISCA-Lung2, a Phase II alisertib trial with paclitaxel. On October 5, 2026, it announced a 7,500-share inducement restricted stock unit award for a new non-executive employee, as BioSpace reported. The October 12, 2026, Q2 update then supplied the revenue and guidance figures that shape the November 5 reporting date.

Dates investors can quantify

The next scheduled event is the Q3 2026 earnings announcement on November 5, 2026, with the conference call set for 4:30 p.m. ET, according to MarketBeat. Its estimate calls for USD 57.50 million of revenue and USD 0.09 in earnings per share, against USD 54.48 million and USD 0.21 in the year-earlier quarter.

Market value and operating context

Puma Biotechnology operates in biotechnology and develops cancer treatments, with NERLYNX as its commercial foundation and alisertib in Phase II development. Its market capitalization was USD 555.4 million on October 20, 2026, while the 52-week range was USD 4.58 to USD 10.84. On Nasdaq, PBYI was last at USD 10.76 on October 20, 2026 at 4:00 p.m. ET.